Regulatory Pathway for Achaogen Looks Better; Is It Aimed At Viable Commercial Market?

With the FDA bottleneck for new anti-infectives showing signs of improvement, the next concern is whether providers will pay high premiums for new anti-infectives and the related challenge of finding the right patients to make high-cost treatments make sense.

As a strategy to increase its chances of FDA approval for the next-generation aminoglycoside anti-infective, plazomicin, Achaogen Inc. changed course after Phase II trials and narrowed the indication from a broad category of gram-negative bacterial infections to carbapenem-resistant Enterobacteriaceae.

As Achaogen explains in its recently filed prospectus for a $75 million initial public offering, “by focusing on the pathogen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America